Treatment of Sarcoidosis with Lupus Pernio in Cutaneous Sarcoidosis

Sarcoidosis can involve the skin in distinct patterns. This protocol addresses the specific presentation of cutaneous sarcoidosis with lupus pernio — a clinical scenario that warrants a targeted therapeutic strategy.

Clinical Scenario

The patient has sarcoidosis with lupus pernio, a form of cutaneous sarcoidosis. Evidence indicates that this particular manifestation responds differently to available therapies, informing the choice of agents in this setting.

Treatment Direction

In cutaneous sarcoidosis with lupus pernio, management involves steroid-sparing agents — antimalarial therapy is a common first step, and cytotoxic agents may be considered alongside or in sequence. The full protocol details agent selection and conditions for use; only a partial summary is given here.

The complete regimen — specifying which agents apply, under which conditions, and in what framework — is available below.

Instant Access to Structured Evidence-Based Regimens

References

For lupus pernio, a large retrospective study reported that anti-TNF therapy was significantly better than cytotoxic or antimalarial therapy, and it could be considered as second-line therapy for this particular form of skin sarcoidosis.
Hydroxychloroquine is often the first steroid-sparing drug used.
Among the cytotoxic drugs, methotrexate seems to have a better response rate than other agents.

View source ↗